Royal London Asset Management Ltd. Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Royal London Asset Management Ltd. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 170,949 shares of the medical device company’s stock after purchasing an additional 7,711 shares during the quarter. Royal London Asset Management Ltd.’s holdings in DexCom were worth $13,295,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at about $25,000. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at about $38,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of DexCom during the 4th quarter valued at about $49,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of recent research reports. Morgan Stanley boosted their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Stock Down 1.7 %

Shares of DXCM opened at $73.80 on Friday. The stock has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The business’s 50 day simple moving average is $83.33 and its 200-day simple moving average is $76.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.